

# Phase III AAD Trial

## Study Basics

- **Disease:** Agitation in Alzheimer's Dementia
- **Phase:** 3
- **Target geography:** Global
- **Total number of sites:** 80

## Background

The sponsor was facing challenges in achieving their patient enrollment targets for an Agitation in Alzheimer's Dementia trial.



## The Problem

The Agitation in Alzheimer's Dementia study opened in 2018. Since the study launched, the sponsor had opened dozens of sites, but had closed many due to slow enrollment. The study team needed help identifying additional AAD experienced sites with access to the patient population, but was unsure how to find them. Furthermore, the study team believed that it had exhausted nearly all patient pools in key AAD geographies, such as South Florida.

With sites experiencing a screening success rate of just 21% and the rising pressure of the approaching 18 month enrollment deadline, they looked to Inato for assistance in finding experienced sites that had the capacity to enroll qualified patients.



## The Solution

The sponsor decided to publish the study on Inato's platform and enable experienced sites to self-select and express their interest in participating. Within three weeks, Inato identified 20 community sites with access to untapped patient populations, including 11 in South Florida that were previously unknown. Ultimately, the sponsor selected 12 Inato sites and activated 10, 8 of which were in Florida.

Due to the condensed timeline, Inato sites had just two months to enroll patients. Inato's involved approach allowed sites to receive the support they needed to enroll in the limited time frame and enabled the sponsor to hit their enrollment targets.

OTHER SITES' SCREENING SUCCESS RATE:

**21%**



INATO'S SITE SCREENING SUCCESS RATE:

**42%**



Sponsor leaders had defined a "good site" as one that could enroll 1 patient every 3 months. On average, Inato sites each enrolled 2 patients over the 2-month enrollment period.

Inato's process of pre-screening patients prior to enrollment allowed their sites to have a screening success rate double that of the other sites in the trial.

With Inato's sites, the sponsor was able to gain access to untapped patient populations and boost the enrollment numbers in their trial. The joint collaboration established a transparent and efficient process, allowing the Inato sites to outperform all other sites in a fraction of the time.

### By the time recruitment closed, Inato sites had...



SCREENED **8x** MORE PATIENTS THAN THE OTHER SITES



RANDOMIZED **16x** MORE PATIENTS THAN THE OTHER SITES

Reach out today to see how Inato can help diversify your site selection.

[EMAIL\\_CONTACT@INATO.COM](mailto:EMAIL_CONTACT@INATO.COM)